Article

A Prescription for Active Surveillance of Prostate Cancer

Leonard Gomella, chair of the urology department and director of the Kimmel Cancer Center Network, explains active surveillance when it comes to a prostate cancer diagnosis.

Leonard Gomella, chair of the urology department and director of the Kimmel Cancer Center Network at Jefferson University Hospitals, explains active surveillance when it comes to a prostate cancer diagnosis.

"Not all patients with prostate cancer require aggressive treatment," he says. "If, in meeting with your doctor, they discuss with you active surveillance versus actively treating the tumor, they need to really explain to you what active surveillance is. It's not that they're ignoring you, but it's keeping an eye on the cancer."

Active surveillance may be different for each practice, but "in general, it's a PSA (prostate-specific antigen test) and a rectal exam about every six month, and every year or two a biopsy of the prostate," he says.

Related Videos
Dr. Azka Ali is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute, in Ohio.
Dr. Michael Bogenschutz
Photo credit: Max Mumby/Indigo via Getty Images
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine, in the Department of Medicine, at Beth Israel Deaconess Medical Center in Boston.
Dr. Stephanie Alice Baker
Dr. Aditya Bardia is a professor in the Department of Medicine, Division of Hematology/Oncology, director of Translational Research Integration, and a member Signal Transduction and Therapeutics, at University of California, Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center.
Dr. Laura Dawson, a professor and chair of the department of Radiation Oncology at the University of Toronto, and a practicing radiation oncologist in the Radiation Medicine Program at Princess Margaret Cancer Center, University Health Network in Toronto.
Dr. Sattva S. Neelapu, a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Michael Bogenschutz, director of the NYU Langone Center for Psychedelic Medicine in New York,
Related Content